Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly

Infection

Volumn 32, Issue 4, 2004, Pages 191-198

  Ruf, B R ^a   Colberg, K ^b   Frick, M ^c   Preusche, A ^b  

^a Klinikum St Georg   (Germany)

^b Medical Practice   (Germany)

^c Medical Practice   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INFECTOVAC FLU; INFLUENZA VACCINE; INFLUSPLIT SSW; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIROSOME VACCINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SKIN INDURATION; VACCINATION REACTION;

EID: 4043130309     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-004-3204-z     Document Type: Article

References (19)

1. Cate TR: Clinical manifestations and consequences of influenza. Am J Med 1987; 82: 15-19.
2. Kohn RR: Cause of death in very old people. JAMA 1982; 247: 2793-2797.
3. Advisory Committee on Immunization Practices (ACIP): Prevention and control of influenza. MMWR 1997; 46 (RR-9): 1-25.
4. Bradley SF: Influenza in the elderly. Prevention is the best strategy in high-risk populations. Postgrad Med 1996; 99: 138-139.
5. Strassburg MA, Greenland S, Sorvillo FJ, Lieb LE, Habel LA: Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. Vaccine 1986; 4: 38-44.
6. Minutello M, Senatore F, Cecchinelli G, Bianchi M, Andreani T, Podda A, Crovari P: Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999; 17: 99-104.
7. De Donato S, Granoff D, Minutello M, Lecchi G, Faccini M, Agnello M, Senatore F, Verweij P, Fritzell B, Podda A: Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999; 17: 3094-3101.
8. Dooley B, Goa KL: Adjuvanted influenza vaccine. BioDrugs 2000; 14: 61-69.
9. Podda A: The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19: 2673-2680.
10. Menegon T, Baldo V, Bonello C, Dalla CD, Di Tommaso A, Trivello R: Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur J Epidemiol 1999; 15: 573-576.
11. Baldo V, Menegon T, Bonello C, Floreani A, Trivello R: Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 2001; 19: 3472-3475.
12. Squarcione S, Sgricia S, Biasio LR, Perinetti E: Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 2003; 21: 1268-1274.
13. Pregliasco F, Mensi C, Serpilli W, Speccher L, Masella P, Belloni A: Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging (Milano) 2001; 13: 38-43.
14. Gluck R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ, Jr.: Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994; 344: 160-163.
15. Van Hoecke C, Prikazsky V, Uto I, Menschikowski C: Immunogenicity of an inactivated split influenza vaccine in institutionalized elderly patients. Gerontology 1996; 42: 190-198.
16. Hehme NW, Kunzel W, Petschke F, Turk G, Raderecht C, Van Hoecke C: Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Invest 2002; 22: 751-769.
17. WHO: Recommended composition of influenza virus vaccines for use in the 2002-2003 season. Wkly Epidem Rec 2002; 77: 62.
18. U.S. Department of Health and Human Services. Influenza virus reagents for the haemagglutination inhibition test. Atlanta (USA): Centers for Disease Control and Prevention. Technical Services Branch 1991.
19. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on Harmonization of Requirements for Influenza Vaccines (CPMP/BWP/214/96).